Trials / Conditions / X-Linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa

16 registered clinical trials studyying X-Linked Retinitis Pigmentosa — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked NCT06646289	Janssen Research & Development, LLC	Phase 2
Active Not Recruiting	A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participan NCT04850118	Beacon Therapeutics	Phase 2 / Phase 3
Enrolling By Invitation	A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR NCT06275620	Beacon Therapeutics	Phase 2
Recruiting	Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa NCT05874310	Frontera Therapeutics	EARLY_Phase 1
Completed	An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa NCT04868916	Janssen Pharmaceutical K.K.	—
Active Not Recruiting	A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mut NCT06333249	Beacon Therapeutics	Phase 2
Active Not Recruiting	Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in th NCT04794101	Janssen Research & Development, LLC	Phase 3
Completed	Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen NCT04671433	Janssen Research & Development, LLC	Phase 3
Active Not Recruiting	4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) NCT04517149	4D Molecular Therapeutics	Phase 1 / Phase 2
Enrolling By Invitation	Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Trea NCT03584165	NightstaRx Ltd, a Biogen Company	Phase 3
Active Not Recruiting	Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutati NCT03316560	Beacon Therapeutics	Phase 1 / Phase 2
Completed	Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) NCT03314207	Beacon Therapeutics	—
Completed	Natural History of the Progression of X-Linked Retinitis Pigmentosa NCT04926129	NightstaRx Ltd, a Biogen Company	—
Completed	Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) NCT03252847	MeiraGTx UK II Ltd	Phase 1 / Phase 2
Completed	Long-term Follow-up Gene Therapy Study for RPGR- XLRP NCT04312672	Janssen Research & Development, LLC	—
Completed	A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 NCT03116113	Biogen	Phase 1 / Phase 2